

Mr Jorge Gallardo Ballart

Professional profile and biography

PHD in Industrial Engineering from the Higher Technical School of Industrial Engineering of Barcelona. He has been Chairman of Almirall since 1988, having previously held various directorship positions in the company since he joined in 1965 (inter alia, the position of CEO until 2011). He was President of EFPIA (European Federation of Pharmaceutical Industries and Associations) between 1998 and 2001, and is currently a member of its Board. He was also President of Farmaindustria between 1993 and 1995, and most recently between 2002 and 2004, while he is currently Vice President.

Other significant Boards to which he may belong, listed public limited companies or otherwise

Grupo Plafin, S.A., Walton, S.L., Goodgrower, S.A.

Member category to which he belongs, as applicable, and indicating, for directors representing controlling shareholders, the shareholder he represents or with whom he is linked

External proprietary member, linked to Grupo Plafin, S.A. and Grupo Corporativo Landon, S.L.

Date of first appointment as company board member, and subsequent appointments

First appointment 30/06/1997, reappointed 18/10/2006, 04/05/2012 and 09/05/2018.

Company shares, and share options, of which he is holder.

He is indirect holder, with his brother Antonio through the company Grupo Plafin, S.A., of 71.429.287 company shares, and indirect holder, with his brother Antonio through the company Grupo Corporativo Landon, S.L., of 43.830.765 company shares.

Mr Daniel Bravo Andreu

Professional profile and biography

Degree in Pharmacy from the Barcelona Central University in 1954. In the sixties he joined as a partner and executive member of the pharmaceutical company Prodes, S.A. with its headquarters in Barcelona, predecessor to the Prodesfarma Group. The laboratory merged with Almirall in 1997 to create Almirall Prodesfarma, S.A., currently Almirall. He has been a Company Board Member since the merger, and currently holds the position of Second Vice President. He is a partner of other non-listed companies in various sectors within the pharmaceutical sector.

Other significant Boards to which he may belong, listed public limited companies or otherwise.

Danimar 1990, S.L.; Danyl 1990, S.L.; Hereter 2001, S.L.

Member category to which he belongs, as applicable, indicating, for directors representing controlling shareholders, the shareholder he represents or with whom he is linked

External member.

Date of first appointment as company board member, and subsequent appointments

First appointment 30/06/1997, reappointed 18/10/2006, 04/05/2012 and 09/05/2018.

Company shares, and share options, of which he is holder

419,723.

Mr Antonio Gallardo Torrededía

Professional profile and biography

Studied at the Universidad de Barcelona (Business Administration and Management) and at the University of Chicago (Executive MBA), he also has a Masters in Marketing from ESADE. He began his career at Akzo Nobel where he stayed for 7 years and became the Marketing Director. In 1999 he

joined Almirall as the Area Manager of the new OTC project. After which he became director of Marketing of pharmacies and developed a loyalty programme consisting of 10,000 pharmacies through the network of medical representatives in Spain. He then became Area Manager, and later Head of the Division of medical representatives and was responsible for over 100 such representatives. In 2008 he left Almirall to pursue the family business, where he was responsible for the area of Real Estate.

Other significant Boards to which he may belong, listed public limited companies or otherwise.

None

Member category to which he belongs, as applicable, indicating, for directors representing controlling shareholders, the shareholder he represents or with whom he is linked

External member linked to Grupo Plafin, S.A.U. and Grupo Corporativo Landon, S.L.

Date of first appointment as company board member, and subsequent appointments

First appointment 25/07/2014 by cooption.

Company shares, and share options, of which he is holder

Direct holder of 182 shares and indirect holder, together with other family members through Grupo Plafin, S.A.U., of 71.429.287 company shares and indirect holder, together with other family members through Grupo Corporativo Landon, S.L., of 43.830.765 company shares.

Mr Carlos Gallardo Piqué

Professional profile and biography

Studied at the Universidad Politècnica de Catalunya (Industrial Engineer) and at the University of Stanford (MBA). With ample experience in the pharma sector, he has held senior positions at Pfizer and at Almirall, specifically in the areas of Licensing, Business Development and Country Management,

having led the negotiations of various product and company acquisitions while at Almirall, such as the German company Hermal and a specific business unit of Shire Pharmaceuticals in the UK. He was named General Manager of Almirall's affiliate in the UK and Ireland. Before his involvement in the pharma sector he worked in the automotive industry as an expert in industrial organization. Since 2014 he has collaborated with a capital risk company identifying and evaluating opportunities in the fields of digital health and medical (medicine) technology.

Other significant Boards to which he may belong, listed public limited companies or otherwise

None.

Member category to which he belongs, as applicable, indicating, for directors representing controlling shareholders, the shareholder he represents or with whom he is linked

External member linked to Grupo Plafin, S.A.U. and Grupo Corporativo Landon, S.L.

Date of first appointment as company board member, and subsequent appointments

First appointment 25/07/2014 by cooption.

Company shares, and share options, of which he is holder

Direct holder of 1.000 shares and indirect holder, together with other family members through Grupo Plafin, S.A.U., of 71.429.287 company shares and indirect holder, together with other family members through Grupo Corporativo Landon, S.L., of 43.830.765 company shares.

Sir Tom McKillop

Professional profile and biography

Sir Tom McKillop started his career in ICI in 1969 following post-doctoral research work in Paris. In ICI Pharmaceuticals Division he held various positions of increasing responsibility in research and development, including Director of Research in France, General Manager (Research) and General

Manager (Development). In 1989 he was appointed Technical Director of ICI Pharmaceuticals, a position in which he was responsible for global Research, Development, Clinical and Production. In 1992 he was appointed Deputy CEO and in 1994 he became CEO of Zeneca Pharmaceuticals. In 1999 he led the merger of Astra and Zeneca, becoming Executive Director of AstraZeneca plc, a position he held until he retired at the end of 2005. Until 2009 he was Chief Executive of the Royal Bank of Scotland and Non-Executive Director of BP. He has also worked as Senior Non-Executive Director of Lloyds TSB Group and was Non-Executive Director of Amersham International before it was acquired by General Electric. He has been President of the European Federation of Pharmaceutical Industries Associations, President of the Pharmaceutical Industry Task Force and a member of the European Round Table of Industrialists and the European Financial Roundtable. He was President of the Science Council from 2008 to 2011.

He has received several academic awards and grants. He is a member of The Royal Society and the Royal Society of Edinburgh, a member of The Academy of Medical Sciences, honorary member of The Royal Society of Chemistry and an honorary member of The Institute of Chemical Engineers.

Other significant Boards to which he may belong, listed public limited companies or otherwise

UCB SA and Evolva Holding SA. He is also part of the Advisory Board of Alsbridge LLP.

Member category to which he belongs, as applicable, indicating, for directors representing controlling shareholders, the shareholder he represents or with whom he is linked

Independent, but proposed to be re-elected as external member

Date of first appointment as company board member, and subsequent appointments

First appointment on 29/05/2007, being again named on 04/05/2012 and on 09/05/2018.

Company shares, and share options, of which he is holder.

No shares, or share options.

Mr Gerhard Mayr

Professional profile and biography

Chairman of the Board of Directors of UCB S.A. (member of the Board since 2005, Chairman since 2012). Member of the Board of Lonza Group Ltd. (since 2006), and member of various board advisory committees. Board member of Vienna, Science, Research and Technology Foundation (since 2002), board member of Project Hope (since 2002) and member of the Circle of Patrons of INSEAD Business School (since 2000).

Previous functions and activities:

- Member of the Board of Alcon, Inc. 2007-2010, until it was acquired by Novartis.
- Member of the Board of OMV AG, 2002-2009.
- Member of the Board of Bank Austria AG, 1998-2006, until it was acquired by Unicredit.
- Member of the U.S. – Egypt President’s Council, Washington, 1999-2004.
- Member of the Board of the European Federation of the Pharmaceutical Industry (1995-1997 and 2000-2002).
- Chairman of the International Executive Committee of the Pharmaceutical Research Manufacturers of America.
- Chairman of the Europe Committee of the Pharmaceutical Research Manufacturers of America.
- He joined Eli Lilly & Company in 1972 as a sales representative. He retired in 2004 as Executive Vicepresident of Global Pharmaceutical Operations. He held directorship positions in the US, Europe, Middle East, Asia and Latin America. As well as Executive Vice President from 1997 to 2004, he was also President of Lilly International, 1993-1997 and President of Lilly Intercontinental, 1997-1999.

Gerhard Mayr has a degree in Chemical Engineering (Dipl.Ing.chem.ETH) from the Swiss Federal Institute of Technology (1969), and an MBA from the Stanford Graduate School of Business (1972). He was awarded the Grand Decoration of Honour in Silver for services to the Republic of Austria and the Decoration of Honour in Gold for services to the State and City of Vienna. He has also been awarded honours from the State of Indiana and the city of Indianapolis.

Other significant Boards to which he may belong, listed public limited companies or otherwise.

UCB, S.A., Lonza Group Ltd., GVKBio.

Member category to which he belongs, as applicable, and indicating, for directors representing controlling shareholders, the shareholder he represents or with whom he is linked.

Independent.

Date of first appointment as company board member, and subsequent appointments.

First appointment 19/10/2012.

Company shares, and share options, of which he is holder.

None.

Ms Karin Louise Dorrepaal

Professional profile and biography

Doctor in medicine from the Free University of Amsterdam following 4 years as research fellow in the Netherlands Cancer Institute. MBA from the Rotterdam School of Management. In 1990 she joined Booz Allen Hamilton Management Consultants, where she stayed until 2004, having been appointed Vice President in 2000. She is specialized in the pharmaceutical industry and has advised large companies in strategy, sales, marketing and supply chain. In 2004 she was appointed member of the Board of Executive Directors of Schering AG. Following the acquisition of the company by Bayer AG, Ms Dorrepaal resigned from her position and currently holds various non-executive positions in a variety of companies including Gerresheimer AG and is on the Industry Board of Triton Private Equity (in Germany), CryoSave, NV (Holland) and MDx Health (Belgium).

Other significant Boards to which he may belong, listed public limited companies or otherwise

No record.

Member category to which she belongs as applicable, indicating, for directors representing controlling shareholders, the shareholder she represents or with whom she is linked

Independent.

Date of first appointment as company board member, and subsequent appointments First appointment

16 November 2012 by co-option, taking effect 1 January 2013.

Company shares, and share options, of which she is holder

5 shares.

Enrique De Leyva Pérez

Professional and biographical profile

Civil Engineer (Civil Engineering School, Madrid). MBA Degree, Columbia Business School. Mr. De Leyva has developed his professional career in high profile companies like Unión Fenosa and McKinsey, in several executive positions. At today's date he is one of the Founding Partners of Magnum Industrial Partners and a Board member and member of the Audit Commission of Indra.

Other Boards of Directors of relevance to which Mr. De Leyva belongs, whether in quoted or non-quoted companies

Indra, Nace, Iberchem, Vendap y Orliman.

Director category

Independent.

Date of first appointment as company board member, and subsequent appointments First appointment

22 February 2019, by co-option.

Shares or options on shares in the Company

None.

